Newron Pharmaceuticals S.p.A.

SWX:NWRN Stock Report

Market Cap: CHF 136.2m

Newron Pharmaceuticals Valuation

Is NWRN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NWRN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: NWRN (CHF7.28) is trading below our estimate of fair value (CHF270.5)

Significantly Below Fair Value: NWRN is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NWRN?

Key metric: As NWRN is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for NWRN. This is calculated by dividing NWRN's market cap by their current revenue.
What is NWRN's PS Ratio?
PS Ratio21.9x
Sales€6.97m
Market Cap€146.57m

Price to Sales Ratio vs Peers

How does NWRN's PS Ratio compare to its peers?

The above table shows the PS ratio for NWRN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average4.8x
COPN Cosmo Pharmaceuticals
5.8x14.2%CHF 993.2m
DESN Dottikon ES Holding
9.5x14.5%CHF 3.2b
IDIA Idorsia
1.9x53.8%CHF 142.0m
SDZ Sandoz Group
1.9x5.7%CHF 17.4b
NWRN Newron Pharmaceuticals
21.9x45.2%CHF 141.7m

Price-To-Sales vs Peers: NWRN is expensive based on its Price-To-Sales Ratio (21.9x) compared to the peer average (4.8x).

Price to Sales Ratio vs Industry

How does NWRN's PS Ratio compare vs other companies in the European Pharmaceuticals Industry?

23 CompaniesPrice / SalesEstimated GrowthMarket Cap
NWRN 21.9xIndustry Avg. 3.1xNo. of Companies33PS0612182430+
23 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: NWRN is expensive based on its Price-To-Sales Ratio (21.9x) compared to the European Pharmaceuticals industry average (3.1x).

Price to Sales Ratio vs Fair Ratio

What is NWRN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NWRN PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio21.9x
Fair PS Ratio10x

Price-To-Sales vs Fair Ratio: NWRN is expensive based on its Price-To-Sales Ratio (21.9x) compared to the estimated Fair Price-To-Sales Ratio (10x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst NWRN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 7.28
CHF 14.42
+98.0%
12.6%CHF 16.94CHF 12.70n/a3
Nov ’25CHF 8.20
CHF 14.42
+75.8%
12.6%CHF 16.94CHF 12.70n/a3
Oct ’25CHF 7.70
CHF 14.42
+87.2%
12.6%CHF 16.94CHF 12.70n/a3
Sep ’25CHF 8.50
CHF 14.30
+68.2%
15.2%CHF 17.31CHF 12.23n/a3
Aug ’25CHF 8.48
CHF 14.30
+68.6%
15.2%CHF 17.31CHF 12.23n/a3
Jul ’25CHF 8.84
CHF 14.30
+61.8%
15.2%CHF 17.31CHF 12.23n/a3
Jun ’25CHF 10.00
CHF 14.45
+44.5%
14.3%CHF 17.29CHF 12.46n/a3
May ’25CHF 8.21
CHF 14.54
+77.2%
14.0%CHF 17.32CHF 12.48n/a3
Apr ’25CHF 7.76
CHF 12.99
+67.4%
4.5%CHF 13.81CHF 12.45n/a3
Mar ’25CHF 8.38
CHF 11.34
+35.3%
22.7%CHF 13.60CHF 7.74n/a3
Feb ’25CHF 7.76
CHF 9.15
+17.9%
26.7%CHF 12.59CHF 7.18n/a3
Jan ’25CHF 4.95
CHF 7.39
+49.3%
3.5%CHF 7.65CHF 7.13n/a2
Dec ’24CHF 4.80
CHF 7.39
+54.0%
3.5%CHF 7.65CHF 7.13n/a2
Nov ’24CHF 4.80
CHF 7.39
+54.0%
3.5%CHF 7.65CHF 7.13CHF 8.202
Oct ’24CHF 5.46
CHF 9.34
+71.1%
29.0%CHF 13.16CHF 7.19CHF 7.703
Sep ’24CHF 5.32
CHF 9.34
+75.6%
29.0%CHF 13.16CHF 7.19CHF 8.503
Aug ’24CHF 5.20
CHF 10.44
+100.8%
30.8%CHF 13.65CHF 7.23CHF 8.482
Jul ’24CHF 6.12
CHF 10.44
+70.6%
30.8%CHF 13.65CHF 7.23CHF 8.842
Jun ’24CHF 3.89
CHF 10.44
+168.4%
30.8%CHF 13.65CHF 7.23CHF 10.002
May ’24CHF 4.44
CHF 10.44
+135.1%
30.8%CHF 13.65CHF 7.23CHF 8.212
Apr ’24CHF 5.78
CHF 10.44
+80.6%
30.8%CHF 13.65CHF 7.23CHF 7.762
Mar ’24CHF 6.04
CHF 8.37
+38.7%
68.9%CHF 14.15CHF 2.60CHF 8.382
Feb ’24CHF 3.12
CHF 8.36
+167.9%
69.0%CHF 14.12CHF 2.59CHF 7.762
Jan ’24CHF 1.55
CHF 8.60
+454.8%
69.7%CHF 14.60CHF 2.60CHF 4.952
Dec ’23CHF 1.35
CHF 8.60
+537.0%
69.7%CHF 14.60CHF 2.60CHF 4.802
Nov ’23CHF 1.29
CHF 8.60
+569.2%
69.7%CHF 14.60CHF 2.60CHF 4.802

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Roche Holding

CHF 200.2b

Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania.

RO

CHF 265.80

7D

-4.8%

1Y

5.6%

Roche Holding

CHF 200.2b

Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania.

ROG

CHF 251.10

7D

-4.0%

1Y

5.3%

Bristol-Myers Squibb

US$100.3b

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.

BMY

US$54.24

7D

0%

1Y

0%